EA201490793A1 - DEPROTEINIZED PREPARATION FROM BLOOD OF CALVES FOR USE IN PREVENTION OR TREATMENT OF POSTINSULTIVE COGNITIVE DISTURBANCES - Google Patents

DEPROTEINIZED PREPARATION FROM BLOOD OF CALVES FOR USE IN PREVENTION OR TREATMENT OF POSTINSULTIVE COGNITIVE DISTURBANCES

Info

Publication number
EA201490793A1
EA201490793A1 EA201490793A EA201490793A EA201490793A1 EA 201490793 A1 EA201490793 A1 EA 201490793A1 EA 201490793 A EA201490793 A EA 201490793A EA 201490793 A EA201490793 A EA 201490793A EA 201490793 A1 EA201490793 A1 EA 201490793A1
Authority
EA
Eurasian Patent Office
Prior art keywords
calves
deproteinized
blood preparation
treatment
preparation
Prior art date
Application number
EA201490793A
Other languages
Russian (ru)
Other versions
EA037642B1 (en
Inventor
Улф Вигониус
Original Assignee
Такеда Австрия Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Такеда Австрия Гмбх filed Critical Такеда Австрия Гмбх
Publication of EA201490793A1 publication Critical patent/EA201490793A1/en
Publication of EA037642B1 publication Critical patent/EA037642B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Feed For Specific Animals (AREA)
  • Fodder In General (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к депротеинизированному препарату из крови телят для применения в профилактике или лечении постинсультных когнитивных нарушений, где депротеинизированный препарат из крови телят вводится парентерально через 0-10 дней после возникновения инсульта по меньшей мере один раз и где за парентеральным введением следует период энтерального введения. В предпочтительном варианте осуществления настоящего изобретения депротеинизированный препарат из крови телят вводится внутривенно после возникновения инсульта один раз в день на протяжении не более 20 дней, и за внутривенным введением следует период перорального введения приблизительно 200 мг депротеинизированного препарата из крови телят три раза в день на протяжении приблизительно 6 месяцев или даже дольше в виде фактически непрерывного лечения. В предпочтительном варианте осуществления настоящего изобретения депротеинизированный препарат из крови телят является лекарственным средством Актовегин®.The present invention relates to a deproteinized blood preparation of calves for use in the prevention or treatment of post-stroke cognitive impairment, where the deproteinized blood preparation from calves is administered parenterally 0-10 days after the onset of stroke at least once, and where parenteral administration is followed by a period of enteral administration. In a preferred embodiment of the present invention, the deproteinized blood preparation of calves is administered intravenously after a stroke has occurred once a day for no more than 20 days, and intravenous administration is followed by a period of oral administration of approximately 200 mg of the deproteinized blood preparation of calves three times a day for approximately 6 months or even longer in the form of virtually continuous treatment. In a preferred embodiment of the present invention, the deproteinized calf blood preparation is Actovegin® medicament.

EA201490793A 2011-10-14 2012-10-15 Deproteinised calf blood preparation for use in prevention or treatment of post-stroke cognitive impairments EA037642B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11185282 2011-10-14
EP12182814 2012-09-03
PCT/EP2012/070375 WO2013053937A1 (en) 2011-10-14 2012-10-15 A deproteinised calf blood preparation for use in prevention or treatment of post-stroke cognitive impairment

Publications (2)

Publication Number Publication Date
EA201490793A1 true EA201490793A1 (en) 2014-07-30
EA037642B1 EA037642B1 (en) 2021-04-26

Family

ID=47010622

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490793A EA037642B1 (en) 2011-10-14 2012-10-15 Deproteinised calf blood preparation for use in prevention or treatment of post-stroke cognitive impairments

Country Status (3)

Country Link
EA (1) EA037642B1 (en)
UA (1) UA116976C2 (en)
WO (1) WO2013053937A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101695140B1 (en) * 2016-06-14 2017-01-11 (주)프로스테믹스 Pharmaceutical composition for prevention and treatment of bone diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1076888B (en) 1956-12-18 1960-03-03 Karl Heinz Jaeger Dr Med Process for the production of active substances that promote breathing for therapeutic purposes
AT330953B (en) 1972-11-16 1976-07-26 Solco Basel Ag METHOD OF MANUFACTURING A PHARMACEUTICAL PREPARATION FOR IMPROVING CELL RESPIRATION

Also Published As

Publication number Publication date
WO2013053937A1 (en) 2013-04-18
EA037642B1 (en) 2021-04-26
UA116976C2 (en) 2018-06-11

Similar Documents

Publication Publication Date Title
EA201690069A1 (en) THE USE OF HIGH DOSE PRIDOPIDINE FOR THE TREATMENT OF THE HANTINGTON'S DISEASE
EA201270221A1 (en) TREATMENT OF CROWN DISEASE WITH LACQUINIMODE
PE20142319A1 (en) MULTIPLE SCLEROSIS TREATMENT WITH A COMBINATION OF LAQUINIMOD AND GLATIRAMER ACETATE
EP4233861A3 (en) Compositions for treatment of essential tremor
CY1118311T1 (en) NITROCATECHOLIS PRODUCTS AS COMT Suspensions Administered By Specific Dosage
AR082150A1 (en) N-ETIL-N-Phenyl-1,2-DIHIDRO-4-HYDROXI-5-CHLORINE-1-METHYL-2-OXOQUINOLIN-3-CARBOXAMIDE DEUTERADA, SALTS AND USES OF THE SAME, TREATMENT METHOD, COMPOUND BLEND, COMPOSITION PHARMACEUTICS, PREPARATION PROCESS, ENRICHED COMPOUND WITH DEUTERIO
NZ714963A (en) Compositions and methods for treating anemia
MX2014002171A (en) Combination treatments for hepatitis c.
MY153062A (en) Methods of treating gastrointestinal disorders independent of the intake of food
BR112015010396A2 (en) combination therapy
EA201492010A1 (en) APPLICATION OF HIGH DOSE OF LACHINIMODE FOR TREATMENT OF MULTIPLE SCLEROSIS
NZ600544A (en) Compositions and methods for the treatment of angiogenesis-related eye diseases
MX2017003780A (en) Pharmaceutical composition for treating ulcerative colitis.
MX2016011333A (en) Drug delivery systems and methods for treatment of bladder cancer with gemcitabine.
RU2013123646A (en) COMBINED COMPOSITION
RU2015116264A (en) COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE IN PATIENTS WITH DIABETES
RU2015112121A (en) MI-RNA AND THEIR APPLICATION IN METHODS AND COMPOSITIONS FOR TREATMENT AND / OR PREVENTION OF EYE CONDITIONS
RU2015115398A (en) N-acetyl-L-cysteine for use in in vitro fertilization
RU2013108390A (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OF PERIOPERATIVE ARTERIAL HYPOTENSION IN HUMAN
EA201490793A1 (en) DEPROTEINIZED PREPARATION FROM BLOOD OF CALVES FOR USE IN PREVENTION OR TREATMENT OF POSTINSULTIVE COGNITIVE DISTURBANCES
FI3352735T3 (en) Sustained release olanzapine formulations
NZ604009A (en) A combination composition comprising ibuprofen and paracetamol
PE20130308A1 (en) METHODS TO TREAT RECURRING BACTERIAL INFECTIONS
NZ597675A (en) Medicament for the long term nsaid use
EA201170502A1 (en) DEPROTEINIZED CALVE PREPARATION FOR USE IN THE PREVENTION OR TREATMENT OF DIABETIC PERIPHERAL POLYNEVROPATIYA